Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SBC Medical Group Holdings (SBC) Cash & Equivalents (2023 - 2025)

SBC Medical Group Holdings (SBC) has disclosed Cash & Equivalents for 3 consecutive years, with $127.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 7.25% year-over-year to $127.4 million, compared with a TTM value of $127.4 million through Sep 2025, down 7.25%, and an annual FY2024 reading of $125.0 million, up 21.38% over the prior year.
  • Cash & Equivalents was $127.4 million for Q3 2025 at SBC Medical Group Holdings, down from $152.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $152.7 million in Q2 2025 and bottomed at $217348.0 in Q1 2023.
  • Average Cash & Equivalents over 3 years is $71.1 million, with a median of $103.0 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 23822.07% in 2024, then fell 7.25% in 2025.
  • Year by year, Cash & Equivalents stood at $103.0 million in 2023, then grew by 21.38% to $125.0 million in 2024, then increased by 1.91% to $127.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for SBC at $127.4 million in Q3 2025, $152.7 million in Q2 2025, and $132.1 million in Q1 2025.